RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q3 FY23 results · Oct–Dec 2022
RPG Life Sciences reported revenue from operations of ₹130.60 crore (up 13.0% from Q3 FY22) and net profit of ₹19.11 crore (up 30.6% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a standalone basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 130.60 | 115.58 | +13.0% | 134.79 | −3.1% |
| Other income | 0.51 | 0.61 | −16.4% | 1.23 | −58.5% |
| Total income | 131.11 | 116.19 | +12.8% | 136.02 | −3.6% |
| Profit before tax | 25.74 | 20.62 | +24.8% | 27.01 | −4.7% |
| Net profit for the period | 19.11 | 14.63 | +30.6% | 19.97 | −4.3% |
| EPS, basic (₹) | 11.56 | 8.85 | +30.6% | 12.08 | −4.3% |
| Net margin (%) | 14.6 | 12.7 | 14.8 |
Standalone
- Filed with BSE
- 07 Feb 2023, 12:36 IST
- Board meeting
- 01 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE